Cited by 696Cancer survivorship and careCancer-related cognitive impairment studiesHealth Systems, Economic Evaluations, Quality of Life

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Esper, Peg, Mo, Fei, Chodak, Gerald, Sinner, Michael, Cella, David, Pienta, Kenneth J.·1997·Urology

DOI 10.1016/s0090-4295(97)00459-7

Open this paper in CoChat — free account

Abstract

Objectives As the incidence of prostate cancer in the United States exceeds 330,000 in 1997, increasingly more men are faced with treatment choices for which there is no clear approach. At every stage of disease, these treatment choices may involve clinically equivalent modalities that differ in side effects and impact upon quality of life (QOL). Comprehensive, yet efficient, questionnaires are needed to measure QOL in patients with prostate cancer.Methods Developed as a disease-specific adjunct to the Functional Assessment of Cancer Therapy (FACT) measurement system, a 12-item prostate cancer subscale (PCS) was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2 (n = 96). The 12 items ask about symptoms and problems specific to prostate cancer. These questions are added to the general (FACT-G) instrument, thereby comprising a 47-item questionnaire.Results Internal consistency of the PCS ranged from 0.65 to 0.69, with coefficients for FACT-G subscales and aggregated scores ranging from 0.61 to 0.90. Concurrent validity was confirmed by the ability to discriminate patients by disease stage, performance status, and baseline prostate-specific antigen (PSA) level. Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change.Conclusions Our findings support use of the FACT-P as a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer.

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(97)00459-7

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citation
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,575
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., Leach, G. E., & Brook, R. H. (1995) · JAMA · doi:10.1001/jama.1995.03520260051032 · Cited by 1,020
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E. J., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Self-citation
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Tannock, I. F., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.129 · Cited by 281
The association of benign prostatic hyperplasia and cancer of the prostate
Bostwick, D. G., Cooner, W. H., Denis, L., Jones, G. W., Scardino, P. T., & Murphy, G. P. (1992) · Cancer · doi:10.1002/1097-0142(19920701)70:1+ · Cited by 222
Early Detection of Prostate Cancer
Scardino, P. T. (1989) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)01800-0 · Cited by 210
Quality of Life and Functional Status Measures in Patients With Head and Neck Cancer
DʼAntonio, L. L., Zimmerman, G. J., Cella, D. F., & Long, S. A. (1996) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1996.01890170018005 · Cited by 197
Self-citation

Show all 22 references

Research works printed but not linked: 2

da Silva, 1993, Quality of life in patients with prostatic cancer. A feasibility study, Cancer, 71, 1138, 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO;2-7 · DOI
Esper, 1995, FACT-P: a new instrument for quality of life evaluation in prostate cancer (abstract), J Urol, 153

Sorted by citations

Items 301–400 of 696

Prostate Cancer and Sleep Disorders: A Systematic Review
Sparasci, D., Napoli, I., Rossi, L., Mestre, R. P., Manconi, M., Treglia, G., Marandino, L., Ottaviano, M., Turco, F., Mangan, D., et al. (2022) · Cancers · doi:10.3390/cancers14071784 · Cited by 20
Prostate cancer: the influence of stigma on quality of life and relationship satisfaction for survivors and their partners
Wood, A. W., Barden, S. M., Terk, M., & Cesaretti, J. (2018) · Journal of psychosocial oncology · doi:10.1080/07347332.2018.1489442 · Cited by 17
Group Exercise versus Personal Training for Prostate Cancer Patients: A Pilot Randomized Trial
Mina, D. S., Ritvo, P., Matthew, A., Rampersad, A., Stein, H., Cheung, A. M., Trachtenberg, J., & Alibhai, S. M. H. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.32020 · Cited by 21
“The MCID for the FACT-P is 5.5 points.”
MethodInfluential
Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer
Wong, C. K. H., Choi, E. P. H., Tsu, J. H., Ho, B., Ng, A. T. L., Chin, W., & Yiu, M. K. (2015) · Quality of Life Research · doi:10.1007/s11136-015-0993-8 · Cited by 21
Lebensqualit�t nach radikalchirurgischen urologischen Eingriffen im Becken und die Bedeutung der Rehabilitation
Dombo, O., & Otto, U. (2004) · Der Urologe · doi:10.1007/s00120-004-0736-x · Cited by 21
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
Iguchi, T., Kimura, G., Fukasawa, S., Suzuki, H., Uemura, H., Nishimura, K., Matsumoto, H., Yokomizo, A., Armstrong, A. J., Rosbrook, B., et al. (2021) · International Journal of Urology · doi:10.1111/iju.14568 · Cited by 20
Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs
Velikova, G., Absolom, K. L., Hewison, J., Holch, P., Warrington, L., AVERY, K. N. L., Richards, H. S., Blazeby, J. M., Dawkins, B., Hulme, C. T., et al. (2022) · Programme Grants for Applied Research · doi:10.3310/fdde8516 · Cited by 21
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
Gudenkauf, L. M., Chavez, M., Maconi, M. L., Geiss, C., Seyedroudbari, A., Thin, P., Hoogland, A. I., Nguyen, K., Murthy, V., Armstrong, W. R., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264946 · Cited by 20
“Commonly used PRO measures (e.g., EORTC QLQ-C30 ( 13 ) and FACT-P ( 14 )) are lengthy and were designed to assess the impacts of conventional therapies (e.g., chemotherapy and radiation).”
MethodSelf-citation
Item Response Theory (IRT): Applications in Quality of Life Measurement, Analysis and Interpretation
Cella, D. F., Chang, C., & Heinemann, A. W. (2002) · Springer eBooks · doi:10.1007/978-1-4757-3625-0_14 · Cited by 19
Self-citation
Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy
Lee, C. E., Kilgour, A. R., & Lau, Y. J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-324 · Cited by 20
“[54,55] HRQOL will be assessed using (12) the Functional Assessment of Cancer Therapy Prostate Module (FACT-P)[56] as a disease-specific global HRQOL instrument.”
Method
The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer
Choi, E. P. H., Wong, C. K. H., Wan, E. Y. F., Tsu, J. H., Chin, W., Kung, K., & Yiu, M. K. (2016) · Quality of Life Research · doi:10.1007/s11136-016-1254-1 · Cited by 20
Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial
Russell, N., Hoermann, R., Cheung, A. S., Ching, M. S., Zajac, J. D., Handelsman, D. J., & Grossmann, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-1072 · Cited by 20
Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study
Jenkins, V. A., Solis‐Trapala, I., Payne, H. A., Mason, M. D., Fallowfield, L. J., May, S. F., Matthews, L., & Catt, S. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.11.001 · Cited by 20
“Quality of Life Table 2 shows the proportion of patients where QoL scores declined, improved or remained the same from baseline to 3 and 6 months for the FACT-P total, PCS, TOI and the FACT-G.”
MethodInfluential
Evaluating quality of life in cancer survivors
Zebrack, B., & Cella, D. F. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545856.011 · Cited by 20
Self-citation
Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy
Kim, S. H., Seong, D. H., Yoon, S. M., Choi, Y. D., Choi, E., & Song, H. (2017) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2017.08.009 · Cited by 20
A new concept in cancer care: The supportive care program
Esper, P., Hampton, J., Finn, J. W., Smith, D. C., REGIANI, S. R., & Pienta, K. J. (1999) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/104990919901600608 · Cited by 20
Self-citation
Outcomes Research: A Methodologic Review
Karakiewicz, P. I., Briganti, A., Chun, F. K. ‐., & Valiquette, L. (2006) · European Urology · doi:10.1016/j.eururo.2006.05.009 · Cited by 20
“HRQOL also represents an important end point in many malignant conditions [28–30].”
Background
Effectiveness of community-based football compared to usual care in men with prostate cancer: Protocol for a randomised, controlled, parallel group, multicenter superiority trial (The FC Prostate Community Trial)
Bjerre, E. D., Bruun, D. M., Tolver, A., Brasso, K., Krustrup, P., Johansen, C., Christensen, R., Rørth, M. R., & Midtgaard, J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2805-0 · Cited by 19
“The primary outcome is change in PCa-specific QoL from baseline to 12 weeks measured with the fourth version of the Functional Assessment of Cancer Therapy – Prostate (FACT-P) questionnaire [28], a self-reported, multidimensional QoL instrument specific for PCa patients [29].”
Method
A systematic review on the efficacy of CBT interventions for the mental and sexual health of survivors of prostate cancer
Pieramico, S., Castro, R., Aguiar, S., Bismarck, F., Ferreira, D. H., Carvalho, J., Quinta-Gomes, A. L., & Nobre, P. J. (2023) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qead024 · Cited by 19
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy
Monk, J. P., Halabi, S., Picus, J., Hussain, A., Philips, G. K., Kaplan, E. B., Ahles, T. A., Gu, L., Vogelzang, N. J., Kelly, W. K., et al. (2011) · Cancer · doi:10.1002/cncr.26732 · Cited by 19
Measuring the individual quality of life of patients with prostate cancer
Stone, P. C., Murphy, R. F., Matar, H. E., & Almerie, M. Q. (2008) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2008.16 · Cited by 19
Transitions in Symptom Cluster Subgroups Among Men Undergoing Prostate Cancer Radiation Therapy
Dirksen, S. R., Belyea, M. J., Wong, W. W., & Epstein, D. R. (2015) · Cancer Nursing · doi:10.1097/ncc.0000000000000236 · Cited by 19
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)
Cathomas, R. L., Crabb, S. J., Mark, M. T., Winterhalder, R. C., Rothermundt, C. A., Elliott, T., von Burg, P., Kenner, H., Hayoz, S., Vilei, S. B., et al. (2016) · The Prostate · doi:10.1002/pros.23236 · Cited by 19
“For the QoL assessment a questionnaire including FACT-P [18] including the FACT-P PCS pain subscale and a global indicator for treatment burden [19] was completed at baseline and on day 1 of each cycle for a maximum of seven cycles.”
The influence of stigma on the quality of life for prostate cancer survivors
Wood, A. W., Barden, S. M., Terk, M., & Cesaretti, J. A. (2017) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2017.1307896 · Cited by 19
Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer
Tonyalı, Ş., Haberal, H. B., & Söğütdelen, E. (2017) · Current Urology · doi:10.1159/000447176 · Cited by 19
An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel ( CAPRISTANA )
Carles, J., Pichler, A., Korunková, H., Tomova, A., Ghosn, M. G., Karak, F. E., Makdessi, J., Королева, И. А., Barnes, G., Bury, D. P., et al. (2018) · British Journal of Urology · doi:10.1111/bju.14509 · Cited by 19
Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results
Alonso-Molero, J., Molina, A. J., Jiménez‐Moleón, J. J., Pérez‐Gómez, B., Martín, V., Moreno, V. R., Amiano, P., Ardanáz, E., de Sanjosé, S., Salcedo-Leal, I., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031904 · Cited by 19
Quality of Life of Men with Biochemical Recurrence of Prostate Cancer
Ames, S. C., Tan, W. W., Ames, G. E., Stone, R. L., Rizzo, T. D., Heckman, M. G., Crook, J. E., Clark, M. M., Rummans, T. A., & Werch, C. E. (2008) · Journal of Psychosocial Oncology · doi:10.1300/j077v26n02_02 · Cited by 19
“The Functional Assessment of Cancer Therapy-Prostate (FACT-P) is a 47-item measure that was administered to evaluate prostate cancer specific QOL (Esper et al., 1997).”
Method
The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients
Arrarás, J. I., Villafranca, E., de la Vega, F. A., Romero, P., Rico, M., Vila, M., Asín, G., Chicata, V., Dominguez, M. A., Laínez, N., et al. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0332-z · Cited by 19
“Other instruments have been developed to assess QL in prostate cancer: these include the Functional Assessment of Cancer Therapy – Prostate (FACT P) [ 8 , 9]; the University of California Los Angeles (UCLA) Prostate Cancer Index (PCI) [10]; the Expanded Prostate Cancer Index Composite (EPIC) [11]; and the PCQOL [12].”
Method
Cancer‐related pain and quality of life in prostate cancer patients: Assessment using the Functional Assessment of Prostate Cancer Therapy
Fujimura, T., Takahashi, S., Kume, H., Takeuchi, T., Kitamura, T., & Homma, Y. (2009) · International Journal of Urology · doi:10.1111/j.1442-2042.2009.02291.x · Cited by 19
A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE
Payne, H. A., Robinson, A., Rappe, B., Hilman, S., Giorgi, U. D., Joniau, S., Bordonaro, R., Mallick, S., Dourthe, L.-M., Flores, M. M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33845 · Cited by 17
Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy
Afferi, L., Longoni, M., Moschini, M., Gandaglia, G., Morgans, A. K., Cathomas, R. L., Mattei, A., Breda, A., Scarpa, R. M., Papalia, R., et al. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00668-0 · Cited by 18
“…QLQ-C30) and its QLQ-PR25 prostate cancer speci ﬁ c module [15, 16], the Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire [17], the European quality of life 5 dimension − 5 levels (EQ-5D-5L) questionnaire [18], the Brief Pain Inventor-Short Form (BPI-SF) [19], and the…”
Home-based exercise improves quality of life in breast and prostate cancer survivors: A meta-analysis
Bates‐Fraser, L. C., Riley, S., Stopforth, C. K., Moertl, K. M., Edgar, K. M., Stoner, L. R., & Hanson, E. D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284427 · Cited by 20
Analysis of health related quality of life (HRQoL) of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy (HDRBT)
Joseph, K. J., Alvi, R., Skarsgard, D., Tonita, J. M., Pervez, N., Small, C., & Tai, P. (2008) · Radiation Oncology · doi:10.1186/1748-717x-3-20 · Cited by 18
Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life
Jiang, X. Y., Atkinson, S., Pearson, R., Leaning, D. J., Cumming, S., Burns, A. W. R., Azzabi, A., Frew, J. A., McMenemin, R. M., & Pedley, I. D. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.05.002 · Cited by 19
Health Disparities of Sexual Minority Patients Following Prostate Cancer Treatment: Results From the Restore-2 Study
Rosser, B. R. S., Polter, E. J., Talley, K. M., Wheldon, C. W., Haggart, R. C., Wright, M., West, W. G., Mitteldorf, D., Ross, M. W., Konety, B. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.812117 · Cited by 18
“Patient reported outcomes were compared to the published EPIC-50, BSI-18, and FACT-P normative samples using t-tests (20–22).”
ResultInfluential
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
Aggarwal, R. R., Alumkal, J. J., Szmulewitz, R. Z., Higano, C. S., Bryce, A. H., Gitlitz, A. M. L., McCarthy, S. A., Miladinović, B., McQuarrie, K., Thomas, S., et al. (2022) · Prostate Cancer · doi:10.1155/2022/5454727 · Cited by 17
Concept and viability of androgen annihilation for advanced prostate cancer
Mohler, J. L. (2014) · Cancer · doi:10.1002/cncr.28675 · Cited by 17
Efficacy, Patient-Reported Outcomes (PROs), and Tolerability of the Changing Therapeutic Landscape in Patients with Metastatic Prostate Cancer (MPC): A Systematic Literature Review
Seal, B. S., Asche, C. V., Puto, K., & Allen, P. D. (2013) · Value in Health · doi:10.1016/j.jval.2013.03.1628 · Cited by 17
Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials
Adamowicz, K. (2016) · Quality of Life Research · doi:10.1007/s11136-016-1429-9 · Cited by 17
Supported progressive resistance exercise training to counter the adverse side effects of robot-assisted radical prostatectomy: a randomised controlled trial
Ashton, R. E. M., Aning, J. J., Tew, G. A., Robson, W. A., & Saxton, J. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06002-5 · Cited by 19
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
Werutsky, G., Maluf, F. C., Cronemberger, E. H., Souza, V. C., Martins, S. P. D. S., Peixoto, F. A., Smaletz, Ò., Schutz, F. A. B., Herchenhorn, D., SANTOS, T. M. D., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5709-y · Cited by 17
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Gratzke, C., Özgüroğlu, M., Peer, A., Şendur, M. A. N., Retz, M. M., Goh, J. C. H., Loidl, W. C., Jayram, G. T., Byun, S., Kwak, C. H., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.008 · Cited by 19
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223
Badrising, S. K., Louhanepessy, R. D., van der Noort, V., Kieffer, J. M., Coenen, J. L. L. M., Hamberg, P., Beeker, A., Wagenaar, N., Lam, M. G. E. H., Celik, F., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00412-6 · Cited by 16
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
Wefel, J. S., Ryan, C. J., Van, J., Jackson, J. C., & Morgans, A. K. (2022) · CNS Drugs · doi:10.1007/s40263-022-00913-5 · Cited by 17
Health-related quality of life of Chinese patients with prostate cancer in comparison to general population and other cancer populations
Choi, E. P. H., Wong, C. K. H., Tsu, J. H., Chin, W., Kung, K., Wong, C. K. W., & Yiu, M. K. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2980-6 · Cited by 16
The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) in prostate cancer patients undergoing androgen deprivation therapy: study protocol for a randomized controlled trial
Focht, B. C., Lucas, A. R., Grainger, E. M., Simpson, C., Thomas‐Ahner, J. M., & Clinton, S. K. (2014) · Trials · doi:10.1186/1745-6215-15-354 · Cited by 16
Examining the influence of illness perception and financial toxicity on the quality of life of prostate cancer patients
Akin‐Odanye, E. O., Ogo, C. N., Sulaiman, F. A., Suleiman, L., Ogunsanya, M. E., & Odedina, F. T. (2021) · African Journal of Urology · doi:10.1186/s12301-021-00173-7 · Cited by 16
“Quality of life (QoL) The validated 39-item Functional Assessment of Cancer Therapy-Prostate (FACTP) instrument [32] was used to assess QoL in the study participants.”
Method
Patient and Physician Reporting of Symptoms and Health-related Quality of Life in Trials of Treatment for Early Prostate Cancer: Considerations for Future Studies
Henderson, A., Andreyev, J. N., Stephens, R. J., & Dearnaley, D. P. (2006) · Clinical Oncology · doi:10.1016/j.clon.2006.09.006 · Cited by 16
Relationship of Mitochondrial Enzymes to Fatigue Intensity in Men With Prostate Cancer Receiving External Beam Radiation Therapy
Filler, K., Lyon, D., McCain, N. L., Bennett, J. P., Fernández‐Martínez, J. L., deAndrés‐Galiana, E. J., Elswick, R. K., Lukkahatai, N., & Saligan, L. N. (2015) · Biological Research For Nursing · doi:10.1177/1099800415617848 · Cited by 16
“The instrument has been validated for use in men with PC (across two samples, internal consistency a ¼ .87–.89; Cella, Nichol, Eton, Nelson, & Mulani, 2009; Esper et al., 1997).”
Method
A pilot feasibility randomized controlled trial adding behavioral counseling to supervised physical activity in prostate cancer survivors: behavior change in prostate cancer survivors trial (BOOST)
Trinh, L., Kramer, A. F., Rowland, K. M., Strom, D. A., Wong, J. N., & McAuley, E. (2020) · Journal of Behavioral Medicine · doi:10.1007/s10865-020-00185-8 · Cited by 17
Oncology Section EDGE Task Force on Prostate Cancer
Harrington, S., Lee, J. Y., Colon, G., & Alappattu, M. J. (2016) · Rehabilitation Oncology · doi:10.1097/01.reo.0000000000000004 · Cited by 16
Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?
Alvisi, M. F., Dordoni, P., Rancati, T., Avuzzi, B., Nicolai, N., Badenchini, F., Luca, L. D., Magnani, T., Marenghi, C., Menichetti, J., et al. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.576459 · Cited by 15
Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives
Kretschmer, A., van den Bergh, R. C. N., Martini, A., Marra, G., Valério, M., Tsaur, I., Heidegger, I. M., Kasivisvanathan, V., Kesch, C. V., Preißer, F., et al. (2021) · Cancers · doi:10.3390/cancers14010147 · Cited by 16
“The Functional Assessment of Cancer Therapy Prostate (FACT-P) questionnaire has been developed in the early 1990s aiming at providing clinicians a multidimensional, userfriendly and versatile tool to assess HRQOL in men with localized and advanced PC [27].”
Background
Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial
Russell, N., Hoermann, R., Cheung, A. S., Zajac, J. D., & Grossmann, M. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0318 · Cited by 15
Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study
Zimmerman, Y., Frydenberg, M., Poppel, H. V., van Moorselaar, R. J. A., Roos, E. P. M., Somford, D. M., Roeleveld, T. A., de Haan, T. D., van Melick, H. H. E., Reisman, Y., et al. (2022) · European Urology Open Science · doi:10.1016/j.euros.2022.09.006 · Cited by 15
“related to pain, appetite, sexual function, and urinary and bowel functions [16,17].”
BackgroundMethod
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
Shen, J., Chowdhury, S., Agarwal, N., Karsh, L. I., Oudard, S. M., Gartrell, B. A., Feyerabend, S., Fred Saad, C., Pieczonka, C. M., Chi, K. N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02492-8 · Cited by 15
“Response to FACT-P items were coded 0 – 4 (from “ very much ” to “ quite a bit ” , “ sometimes ” , “ a little bit ” and “ not at all ” ); the sum for all responses ranges from 0 to 156, higher scores indicating better HRQoL [17, 23].”
BackgroundMethod
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial
Rathkopf, D. E., Roubaud, G., Chi, K. N., Efstathiou, E., Attard, G., Olmos, D., Small, E. J., Saad, M. B., Castro, E., Kim, W. B., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.09.003 · Cited by 15
Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life
Liu, Y., Uemura, H., Ye, D., Lee, J. Y., Chiong, E., Pu, Y., Razack, A. H. A., Pripatnanont, C., Rawal, S. K., Low, G. K. M., et al. (2018) · Prostate International · doi:10.1016/j.prnil.2018.12.001 · Cited by 15
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
Fallah, J., Zhang, L., Amatya, A. K., Gong, Y. U. T., King‐Kallimanis, B. L., Bhatnagar, V., Weinstock, C., Suzman, D. L., Agrawal, S., Chang, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00334-x · Cited by 15
Patient reported outcomes and health related quality of life in localized prostate cancer: A review of current evidence
Kord, E., Flores, J. P., Posielski, N. M., Koenig, H. G., Ho, O., & Porter, C. R. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.04.008 · Cited by 15
Validation of the Intestinal Part of the Prostate Cancer Questionnaire “QUFW94”: Psychometric Properties, Responsiveness, and Content Validity
Reidunsdatter, R. J., Lund, J., Fransson, P., Widmark, A., Fosså, S. D., & Kaasa, S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.057 · Cited by 15
The effects of prostate cancer on intimate relationships
Couper, J. W. (2007) · The Journal of Men s Health and Gender · doi:10.1016/j.jmhg.2007.04.008 · Cited by 15
“Research suggests that prostatectomy and radiation therapy produce similar prospects for survival [16].”
Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients
Anota, A., Mariet, A., Maingon, P., Joly, F., Bosset, J.-F., Guizard, A., Bittard, H., Velten, M., & Mercier, M. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0571-y · Cited by 14
Meaningful differences and validity for the NCCN/FACT‐P Symptom Index: An analysis of the ALSYMPCA data
Beaumont, J. L., Butt, Z. A., Li, R., & Cella, D. F. (2019) · Cancer · doi:10.1002/cncr.31973 · Cited by 14
“The FACT-P consists of 27 items from the Functional Assessment of Cancer Therapy–General (FACT-G) that measure physical, social/family, emotional, and functional well-being and 12 items that compose the Prostate Cancer Subscale (PCS).(7) In addition, 2 prostate cancer pain subscales have been developed from these 39 i…”
MethodSelf-citation
Unrecognized sexual dysfunction in gay and bisexual men after prostate cancer treatment: the antecedents and impact of anodyspareunia
Wheldon, C. W., Bates, A. J., Polter, E. J., Rosser, B. R. S., Kapoor, A., Talley, K. M., Haggart, R. C., Kohli, N., Konety, B. R., Mitteldorf, D., et al. (2023) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdad009 · Cited by 14
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials
Persson, A. E., Hallqvist, A., Larsen, L. B., Rasmussen, M., Scherman, J. B., Nilsson, P. G., Tønnesen, H., & Gunnlaugsson, A. (2024) · Radiation Oncology · doi:10.1186/s13014-024-02559-7 · Cited by 14
“…of Cancer Therapy-General (FACT-G) version 4 total score [41], Functional Assessment of Cancer Therapy-Prostate (FACT-P) version 4 total score [42], or according to the study authors, at 3 months; HRQoL at 5 years or longest follow-up; and systemic therapy-free survival, defined as time from…”
Cancer symptom response as an oncology clinical trial end point
Bouchard, L. C., Aaronson, N. K., Gondek, K., & Cella, D. F. (2018) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2018.1483193 · Cited by 15
Self-citation
Implementation of patient-reported outcome measures into health care for men with localized prostate cancer
Singhal, U., Skolarus, T. A., Gore, J. L., Parry, M. G., Chen, R. C., Nossiter, J., Cruz, A. P., George, A. K., Cathcart, P. J., van der Meulen, J., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00575-4 · Cited by 14
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Guidance for Use in Research and Clinical Practice
Webster, K., Peipert, J. D., Lent, L., Bredle, J. M., & Cella, D. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-84702-9_6 · Cited by 14
Self-citation
Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the J‐ROCK study
Uemura, H., Matsumoto, R., Mizokami, A., Miyake, H., Uemura, H., Matsuyama, H., Nakamura, K., Saito, K., Kawakita, M., Takeshita, H., et al. (2022) · International Journal of Urology · doi:10.1111/iju.14993 · Cited by 14
Treatment-related toxicity and symptom-related bother followingpostoperative radiotherapy for prostate cancer
Sia, M. A., Rodrigues, G., Ménard, C. M., Bayley, A., Bristow, R. G., Chung, P. W. M., Gospodarowicz, M. K., Milosevic, M., Warde, P. R., & Catton, C. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.801 · Cited by 14
Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials
Robinson, D. W., Zhao, N., Dawkins, F. W., Qi, M., & Revicki, D. A. (2013) · Quality of Life Research · doi:10.1007/s11136-013-0411-z · Cited by 14
Quality-of-life assessment tools for men with prostate cancer
Bergman, J., & Laviana, A. A. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.101 · Cited by 14
Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer
Arlen, P. M., & Gulley, J. L. (2005) · Future Oncology · doi:10.1517/14796694.1.1.19 · Cited by 14
“The quality of life was assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire [11].”
Method
The Relationships Between Spiritual Well-Being, Quality of Life, and Psychological Factors Before Radiotherapy for Prostate Cancer
Walker, S. J., Chen, Y., Paik, K., Mirly, B., Thomas, C. R., & Hung, A. (2016) · Journal of Religion and Health · doi:10.1007/s10943-016-0352-2 · Cited by 16
Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab)
Yachnin, J., Gilje, B., Thon, K., Johansson, H., Brandberg, Y., Panaretakis, T., & Ullén, A. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.007 · Cited by 14
Patient-reported Outcome Measures in Metastatic Urinary Cancers
Bergerot, C. D., Bergerot, P. G., Philip, E. J., & Pal, S. K. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.02.020 · Cited by 13
Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice
Joly, F., Oudard, S. M., Fizazi, K. S., Tubach, F., Jové, J., Lacueille, C., Lamarque, S., Guiard, E., Balestra, A., Droz‐Perroteau, C., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.02.003 · Cited by 14
Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer
Shore, N. D., Schellhammer, P. F., Tutrone, R. F., Jr., Mariados, N. F., & Harrelson, S. S. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.02.015 · Cited by 14
Health-Related Quality of Life
Litwin, M. S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-230-4_13 · Cited by 16
Plasma chromogranin A: Clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy
Sarkar, D., Singh, S. K., Mandal, A. K., Agarwal, M. M., Mete, U. K., Kumar, S., Mavuduru, R. S., & Prasad, R. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0198 · Cited by 14
“pedal oedema) and quality of life [Functional Assessment of Cancer Therapy – Prostate (FACT-P) questionnaire] [23].”
Background
Developing a Self-Report Outcome Measure for Complementary and Alternative Medicine
Eton, D. T., Koffler, K., Cella, D. F., Eisenstein, A., Astin, J. A., Pelletier, K. R., & Riley, D. S. (2005) · EXPLORE · doi:10.1016/j.explore.2005.02.007 · Cited by 14
Self-citation
Quality of Life endpoints in prostate chemoprevention trials
Sloan, J. A., & Varricchio, C. G. (2001) · Urology · doi:10.1016/s0090-4295(00)00982-1 · Cited by 14
Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need?
Colloca, G. A., & Colloca, P. (2010) · Medical Oncology · doi:10.1007/s12032-010-9495-2 · Cited by 13
Análisis de satisfacción en varones que presentaban cáncer de próstata localizado tratados con prostatectomía radical o radioterapia: Aspectos Psicológicos y Sociales
Gugliotta, A., Ferreira, U., Reis, L. O., Matheus, W. E., Denardi, F., Stopiglia, R., & Naccarato, A. M. E. P. (2008) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(08)73855-5 · Cited by 13
Improving quality of life among latino cancer survivors: Design of a randomized trial of patient navigation
Ramírez, A. G., Gallion, K. J., Perez, A., Muñoz, E., Parma, D. L., Moreno, P. I., & Penedo, F. J. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.11.002 · Cited by 12
Quality of life, depression, and psychosocial mechanisms of suicide risk in prostate cancer
Tripp, D. A., Mihajlovic, V., Fretz, K. M., Fervaha, G., Izard, J., Corby, R., & Siemens, D. R. (2019) · Canadian Urological Association Journal · doi:10.5489/cuaj.6310 · Cited by 16
Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials
Hui, D., Darke, A. K., Guthrie, K. A., Subbiah, I. M., Unger, J. M., Hershman, D. L., Krouse, R. S., Bakitas, M. A., & O’Rourke, M. A. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00407 · Cited by 13
The effects of androgen deprivation on working memory and quality of life in prostate cancer patients: The roles of hypothalamic connectivity
Chaudhary, S., Zhornitsky, S., Roy, A. M., Summers, C., Ahles, T. A., Li, C.-S. R., & Chao, H. H. (2022) · Cancer Medicine · doi:10.1002/cam4.4704 · Cited by 12
A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
Lee, C. E., Leslie, W. D., & Lau, Y. J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-103 · Cited by 13
Measuring quality of life in prostate cancer: progress and challenges
Litwin, M. S., & Talcott, J. A. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545856.006 · Cited by 13
Racial differences in well-being and cancer concerns in prostate cancer patients
Chhatre, S., Wein, A. J., Malkowicz, S. B., & Jayadevappa, R. (2011) · Journal of Cancer Survivorship · doi:10.1007/s11764-011-0170-1 · Cited by 13
“FACT-P has demonstrated good psychometric properties with internal consistency alpha ranging between 0.87 and 0.89 [ 17 ].”
BackgroundMethodInfluential
Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China
Ye, D., Zhang, W., Ma, L., Du, C., Xie, L., Huang, Y., Wei, Q., Ye, Z., & Na, Y.-Q. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.03.13 · Cited by 13
Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force
Villa, S., Kendel, F., Venderbos, L. D. F., Rancati, T., Bangma, C. H., Carroll, P. R., Denis, L., Klotz, L. H., Korfage, I. J., Lane, J. A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.09.041 · Cited by 12
“In addition, use of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire was suggested as a PCa-specific tool [9].”
Method
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Unger, J. M., Griffin, K., Donaldson, G. W., Baranowski, K., Good, M. J., Reburiano, E., Hussain, M., Monk, P., Veldhuizen, P. J. V., Carducci, M. A., et al. (2018) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-018-0054-5 · Cited by 12
Sexual function outcomes following interventions for prostate cancer: are contemporary reports on functional outcomes misleading?
Lovegrove, C. E., Ficarra, V., Montorsi, F., N'Dow, J. M., Salonia, A., & Minhas, S. (2019) · International Journal of Impotence Research · doi:10.1038/s41443-019-0220-1 · Cited by 12
Virtual care for prostate cancer survivorship: protocol for an evaluation of a nurse-led algorithm-enhanced virtual clinic implemented at five cancer centres across Canada
Phạm, Q., Hearn, J., Bender, J. L., Berlín, A., Brown, I., Bryant‐Lukosius, D., Feifer, A. H., Finelli, A., Gotto, G. T., Hamilton, R. J., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045806 · Cited by 13
Treatment Regret, Mental and Physical Health Indicators of Psychosocial Well-Being among Prostate Cancer Survivors
Bradley, C., Ilie, G., MacDonald, C., Massoeurs, L., Vo, J. D. C.-T., & Rutledge, R. D. H. (2021) · Current Oncology · doi:10.3390/curroncol28050333 · Cited by 12
Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054)
Dawson, N. A., Payne, H. A., Battersby, C., Taboada, M., & James, N. D. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0864-1 · Cited by 12
“…are commonly used in randomized clinical trials of patients with prostate cancer; the Functional Assessment of Cancer Therapy-Prostate (FACT-P) (Esper et al. 1997) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (Aaronson et al.…”
BackgroundMethod

Authors: Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J.
Affiliations: Rush University Medical Center (US)
Corresponding author: Esper, Peg
ORCID: Cella, David
Pienta, Kenneth J.
Venue: Urology
Publisher: Elsevier BV
Published: 1997-12
Volume: 50
Issue: 6
Pages: 920-928
ISSN: 0090-4295 (ISSN-L)
DOI: 10.1016/s0090-4295(97)00459-7
OpenAlex: W2004909463
Cited by: 696
References: 22
Citations by year: 2026: 18 · 2025: 22 · 2024: 34 · 2023: 25 · 2022: 45 · 2021: 34 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 29 · 2016: 33 · 2015: 30 · 2014: 28 · 2013: 31 · 2012: 27
FWCI: 4.00
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Urology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords: prostate cancer, quality of life, Functional Assessment of Cancer Therapy, questionnaire development, concurrent validity, internal consistency, sensitivity to change, prostate-specific antigen, performance status, disease stage
MeSH terms: Aged, Aged, 80 and over, Chicago, Humans, Male, Michigan, Middle Aged, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Reproducibility of Results

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks